Where salivary gland cancer treatment is heading
Salivary gland cancer · Updated Nov 14, 2026
Salivary gland cancers start in the parotid and other glands that make saliva; a few thousand Americans are diagnosed each year. There are more than 20 types, including mucoepidermoid carcinoma, adenoid cystic carcinoma and salivary duct carcinoma, which behave very differently. Surgery, often with radiation, cures many early cancers, but there has been no standard drug treatment for advanced disease. That is changing as tumors are tested for HER2, androgen receptors and other targets, with matched drugs giving high response rates.
- 64studies open or running
- 3phase 3 trials
- 423papers published this year
- 11NIH-funded projects
-
Now
Nov 2026
HER2-targeted drugs work wellHappened 91.7% response rate
A HER2 antibody-drug conjugate shrank 91.7% of HER2-high tumors; trastuzumab plus docetaxel shrank 60.0%.
91.7%: response rate in HER2-high disease.
Hormone blockade for androgen-receptor-positive tumorsHappened 45.2% response rate
Darolutamide plus goserelin shrank 45.2% of tumors, without chemotherapy.
45.2%: response rate with darolutamide plus goserelin.
Adenoid cystic carcinoma remains hard to shrinkHappened 45% progression-free at 6 months
Regorafenib slowed growth (45% progression-free at 6 months) but shrank no tumors.
45%: progression-free at 6 months.
-
6 months
by May 2027
Chemotherapy with radiation after surgeryPossible
RTOG 1008 (252 people), testing whether cisplatin improves postoperative radiation for high-risk cancers, finishes December 2026.
-
12 months
by Nov 2027
A HER2 bispecific antibodyPossible
Jazz's zanidatamab study (200 people, including salivary cancers) finishes December 2026.
Routine tumor testingLikely 45.5% response in HER2-low
Testing for HER2, androgen receptor, NTRK and other targets is becoming standard for advanced disease.
45.5%: response rate in HER2-low disease.
-
3 years
by late 2029
T-DM1 vs chemotherapyPossible 60.0% response (trastuzumab-docetaxel)
NRG-HN010 (146 people) compares the HER2 drug conjugate T-DM1 with chemotherapy; due July 2028.
60.0%: response rate.
-
5 years
by late 2031
Better treatment after surgeryPossible
SANTAL (342 people) tests chemoradiation vs radiation alone after surgery; due February 2030.
TROP2 drug conjugatesLong shot
A trial of sacituzumab tirumotecan targets TROP2, which most adenoid cystic carcinomas carry; due April 2030.
The research paths
HER2-targeted drugs
91.7% response rateDetails and 4 trialsHide
Antibodies, drug conjugates and bispecifics for HER2-positive and HER2-low tumors.
WatchNRG-HN010; zanidatamab.
- T-DM1 vs chemotherapy for HER2-positive disease (NRG-HN010)NRG Oncology · 146 people · enrolling Jul 2028
- Trastuzumab plus pertuzumab (DETERMINE arm 04)Cancer Research UK · 30 people · enrolling Oct 2029
- Zanidatamab, a HER2 bispecific antibodyJazz Pharmaceuticals · 200 people · enrolling Dec 2026
- T-DM1 after surgery for HER2-positive diseaseDana-Farber Cancer Institute · 37 people · enrolling Feb 2028
Hormone therapy
45.2% response rateDetails and 1 trialsHide
Androgen receptor blockers borrowed from prostate cancer.
WatchNCI darolutamide trial.
Radiation and adenoid cystic carcinoma
45% progression-free at 6 monthsDetails and 4 trialsHide
Optimizing treatment after surgery, and new approaches for adenoid cystic carcinoma.
WatchRTOG 1008; SANTAL.
- Radiation with or without cisplatin after surgery (RTOG 1008)NRG Oncology · 252 people · fully enrolled Dec 2026
- Chemoradiation vs radiation after surgery (SANTAL)GORTEC · 342 people · fully enrolled Feb 2030
- Lenvatinib plus pembrolizumab for adenoid cystic carcinomaMemorial Sloan Kettering · 64 people · fully enrolled Dec 2026
- Sacituzumab tirumotecan (TROP2 drug conjugate)Latin American Cooperative Oncology Group · 64 people · not yet open Apr 2030
Borrowed from other cancers
From Prostate cancer
Darolutamide
Phase 2
An androgen receptor blocker approved for prostate cancer.
From Breast and stomach cancer
Trastuzumab and HER2 drug conjugates
Phase 2/3
HER2-targeted drugs first approved for breast cancer.
From Breast and lung cancer
Sacituzumab tirumotecan
Phase 2
A TROP2-directed drug conjugate.
Open to join now
-
HER2-positive salivary cancer
T-DM1 vs chemotherapy
Locations and eligibility → -
HER2-positive rare cancers
Trastuzumab plus pertuzumab
Locations and eligibility → -
HER2-expressing tumors
Zanidatamab
Locations and eligibility → -
HER2-positive salivary cancer
T-DM1 after surgery
Locations and eligibility →
See every recruiting Salivary gland cancer trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
HER2 drug conjugate shrinks 91.7% of HER2-high tumors
J Clin Oncol.
Darolutamide plus goserelin shrinks 45.2% of tumors
DISCOVARY, J Clin Oncol.
Standard treatment today
- Early, low gradeSurgery alone.
- Higher risk after surgeryRadiation; chemotherapy added in some cases (being tested).
- Advanced, HER2-positiveTrastuzumab-based treatment or a HER2 antibody-drug conjugate.
- Advanced, androgen-receptor-positiveAndrogen blockade; chemotherapy or clinical trials otherwise.
How to read this page, and sourcesHow to read this page, and sources
- Salivary gland cancer includes many types; results for one (such as salivary duct carcinoma) may not apply to others (such as adenoid cystic carcinoma).
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Salivary gland cancer trials recruiting now →